Twist Bioscience Expands Synthetic Viral Controls Portfolio With Launch Of Synthetic RNA Control For H5N1 Influenza A; Covers 99.9% Of Hemagglutinin And Neuraminidase Genome Regions
Twist Bioscience Expands Synthetic Viral Controls Portfolio With Launch Of Synthetic RNA Control For H5N1 Influenza A; Covers 99.9% Of Hemagglutinin And Neuraminidase Genome Regions
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.